

NEWSLETTER

ACUTE LEUKEMIA WORKING PARTY OF EBMT

A WORD FROM THE CHAIRMAN

Dear Friends and Colleagues,

It is a great pleasure to send you the latest newsletter of the Acute Leukemia Working Party (ALWP) of EBMT, summarizing our ongoing activities. This editorial is also a good opportunity to offer some personal and general thoughts.

As you know, the EBMT through its different working parties and committees aims to allow scientists and physicians involved in stem cell transplantation and cellular therapy to share their experience and develop co-operative studies. The ALWP which relies on a large registry based in Paris is specifically devoted to the promotion and analyses of all acute leukemia aspects associated with the transplantation of stem cells from all donor sources and donor types including prospective and retrospective studies, and education in this field. Over the last decades, studies conducted by the ALWP members yielded a significant amount of scientific knowledge creating the basis for continuously improving patient care.

With the support of the different ALWP sub-committees leaders (F. Ciceri, J. Esteve, S. Giebel, NC. Gorin, A. Nagler, and C. Schmid), the data managers (E. Polge, and L. Moukhtari), our dedicated statistician M. Labopin, ALWP members and all EBMT participating centres (whom I

thank for their hard work and wonderful contributions), the studies portfolio of the ALWP has grown quickly, and generated an amazing number of published manuscripts and communications at major meetings such as the EBMT and ASH meetings. Despite these nice achievements, in the context of low resources setting and strong worldwide scientific competition, the ALWP (like most other EBMT working parties) is facing many logistical obstacles, and thus the practical difficulties (study coordination, data entry and management, etc.) in conducting and finalising studies in a timely fashion according to the highest scientific standards, should not be ignored. Despite these hard challenges, the leadership and staff of the ALWP managed to find solutions, and always replied positively to all submitted proposals. The huge scientific productivity of the ALWP over the last months is a good illustration of the success of such strategy. Thus, with the support of all of you, I deeply believe in the capacity of the ALWP in cooperation with the other working parties and EBMT leadership, to continue daunting these challenges.

I do thank you all for your continuous support to the ALWP endeavours and you can count on my commitment to boost the scientific drive of the investigators towards conducting large, well-

designed and innovative studies.

Prof. Mohamad Mohty, MD,
PhD

*Chairman, ALWP of EBMT
Paris, France (CIC 775)*

Chairman

Mohamad MOHTY
Saint Antoine
Hospital
Paris, France

Email :

mohamad.mohty@inserm.fr



Secretary

Sebastien GIEBEL
Maria Sklodowska-
Curie Memorial
Cancer Centre &
Oncology Institute
Gliwice, Poland

Email : sgiebel@io.gliwice.pl



ALWP STUDIES PUBLISHED OR
ACCEPTED IN 2012

1. The impact of center experience on results of reduced intensity: allogeneic hematopoietic SCT for AML. An analysis from the Acute Leukemia Working Party of the EBMT. *Bone Marrow Transplant.* 2012 Jul 9. doi: 10.1038/bmt.2012.131. Giebel S, Labopin M, Mohty M, Mufti GJ, Niederwieser D, Cornelissen JJ, Janssen JJ, Milpied N, Vindelov L, Petersen E, Arnold R, Bacigalupo A, Blaise D, Craddock C, Nagler A, Frassoni F, Sados-Wojciechowska M, Rocha V.
2. Clofarabine containing conditioning regimen for allo-SCT in AML/ALL patients: a survey from the Acute Leukemia Working Party of EBMT. *Eur J Haematol.* 2012 Jun 16. Chevallier P, Labopin M, Buchholz S, Ganser A, Ciceri F, Lioure B, Faul C, Guillermin G, Finke J, Huynh A, Schubert J, Kolb HJ, Polge E, Nagler A, Mohty M.
3. Impact of graft-versus-host disease after reduced-intensity conditioning allogeneic stem cell transplantation for acute myeloid leukemia: a report from the Acute Leukemia Working Party of the European group for blood and marrow transplantation. *Leukemia.* 2012 May 22. Baron F, Labopin M, Niederwieser D, Vigouroux S, Cornelissen JJ, Malm C, Vindelov LL, Blaise D, Janssen JJ, Petersen E, Socié G, Nagler A, Rocha V, Mohty M.
4. Mobilized peripheral blood stem cells compared with bone marrow from HLA-identical siblings for reduced-intensity conditioning transplantation in acute myeloid leukemia in complete remission: a retrospective analysis from the Acute Leukemia Working Party of EBMT. *Eur J Haematol.* 2012 May 31. doi: 10.1111/j.1600-0609.2012.01811.x. [Epub ahead of print]. Nagler A, Labopin M, Shimoni A, Mufti GJ, Cornelissen JJ, Blaise D, Janssen JJ, Milpied N, Vindelov L, Petersen E, Gribben J, Bacigalupo A, Malm C, Niederwieser D, Socié GJ, Arnold R, Brown P, Goker H, Rocha V, Mohty M; The ALWP-EBMT.
5. Bone marrow or peripheral blood stem cell transplantation from unrelated donors in adult patients with acute myeloid leukaemia, an Acute Leukaemia Working Party analysis in 2262 patients. *J Intern Med.* 2012 Apr 20. doi: 10.1111/j.1365-2796.2012.02547.x. [Epub ahead of print]. Ringdén O, Labopin M, Beelen DW, Volin L, Ehninger G, Finke J, Greinix HT, Kyrz-Krzemien S, Bunjes D, Brinck L, Niederwieser D, Arnold R, Mohty M, Rocha V.
6. Impact of cytogenetics risk on outcome after reduced intensity conditioning allo-SCT from an HLA-identical sibling for patients with AML in first CR: a report from the acute leukemia working party of EBMT. *Bone Marrow Transplant.* 2012 Apr 16. doi: 10.1038/bmt.2012.55. [Epub ahead of print] Chevallier P, Labopin M, Milpied N, Cornelissen JJ, Blaise D, Petersen E, Sandstedt A, Goker H, Socie G, Rocha V, Mohty M.
7. Mobilized Peripheral Blood Stem Cells Compared with Bone Marrow as the Stem Cell Source for Unrelated Donor Allogeneic Transplantation with Reduced-Intensity Conditioning in Patients with Acute Myeloid Leukemia in Complete Remission: An Analysis from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation. *Biol Blood Marrow Transplant.* 2012 Mar 20. [Epub ahead of print] Nagler A, Labopin M, Shimoni A, Niederwieser D, Mufti GJ, Zander AR, Arnold R, Greinix H, Cornelissen JJ, Jackson GH, Craddock C, Bunjes DW, Ganser A, Russell NH, Kyrz-Krzemien S, Rocha V, Mohty M.
8. Growth factor-associated graft-versus-host disease and mortality 10 years after allogeneic bone marrow transplantation. *Br J Haematol.* 2012 Apr;157(2):220-9. doi: 10.1111/j.1365-2141.2012.09034.x. Epub 2012 Feb 2. Ringdén O, Labopin M, Gorin NC, Volin L, Torelli GF, Attal M, Jouet JP, Milpied N, Socié G, Cordonnier C, Michallet M, Atienza AI, Hermine O, Mohty M.
9. Impact of FLT3 internal tandem duplication on the outcome of related and unrelated hematopoietic transplantation for adult acute myeloid leukemia in first remission: a retrospective analysis. *J Clin Oncol.* 2012 Mar 1;30(7):735-41. Epub 2012 Jan 30. Brunet S, Labopin M, Esteve J, Cornelissen J, Socié G, Iori AP, Verdonck LF, Volin L, Gratwohl A, Sierra J, Mohty M, Rocha V.
10. Outcomes and prognostic factors of adults with acute lymphoblastic leukemia who relapse after allogeneic hematopoietic cell transplantation. An analysis on behalf of the Acute Leukemia Working Party of EBMT. *Leukemia.* 2012 Jun;26(6):1211-7. doi: 10.1038/leu.2011.351. Epub 2012 Jan 31. Spyridonidis A, Labopin M, Schmid C, Volin L, Yakoub-Agha I, Stadler M, Milpied N, Socie G, Browne P, Lenhoff S, Sanz MA, Aljurf M, Mohty M, Rocha V.
11. Treatment, risk factors, and outcome of adults with relapsed AML after reduced intensity conditioning for allogeneic stem cell transplantation. *Blood.* 2012 Feb 9;119(6):1599-

606. Epub 2011 Dec 13. Schmid C, Labopin M, Nagler A, Niederwieser D, Castagna L, Tabrizi R, Stadler M, Kuball J, Cornelissen J, Vorlicek J, Socié G, Falda M, Vindeløv L, Ljungman P, Jackson G, Kröger N, Rank A, Polge E, Rocha V, Mohty M.

12. The European LeukemiaNet AML Working Party consensus statement on allogeneic HSCT for patients with AML in remission: an integrated-risk adapted approach. *Nat Rev Clin Oncol*. 2012 Sep 4;9(10):579-90. doi: 10.1038/nrclinonc.2012.150. Epub 2012 Sep 4. Cornelissen JJ, Gratwohl A, Schlenk RF, Sierra J, Bornhäuser M, Juliusson G, Râcil Z, Rowe JM, Russell N, Mohty M, Löwenberg B, Socié G, Niederwieser D, Ossenkoppele GJ.

13. Impact of FLT3 ITD/NPM1 mutation status in adult patients with acute myelocytic leukemia autografted in first remission. *Haematologica*. 2012 Aug 28. [Epub ahead of print] Gorin NC, Labopin M, Meloni G, Pigneux A, Esteve J, Mohty M.

ALWP ORAL PRESENTATIONS DURING ASH 2012

(ATLANTA, GA – December 8-11,

1. Publication Number: 233

TITLE: *Autologous HSCT for Ph-Positive Adult Acute Lymphoblastic Leukemia: A Curative Option in the Era of Tyrosine Kinase Inhibitors? an Analysis From the Acute Leukemia Working Party of the EBMT*

Session Name: 731. Clinical Allogeneic and Autologous Transplantation - Results: Clinical Transplantation for Acute Leukemia

Session Date: Sunday, December 9, 2012

Session Time: 4:30 PM - 6:00 PM

Presentation Time: 5:30 PM

Room: Georgia World Congress Center, B312-313a

Presenter: Dr S. Giebel

2. Publication Number: 356

TITLE: *Myeloablative Allogeneic Hematopoietic Stem Cell Transplantation for Adult Patients with T-Cell Acute Lymphoblastic Leukemia: A Survey From the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT)*

Session Name: 731. Clinical Allogeneic and Autologous Transplantation - Results: Allogeneic Transplantation for Leukemia and MDS

Session Date: Monday, December 10, 2012

Session Time: 7:00 AM - 8:30 AM

Presentation Time: 7:15 AM

Room: Georgia World Congress Center, B312-313a

Presenter: Dr X. Cahu

3. Publication Number: 734

TITLE: *Prediction of Non-Relapse Mortality in Recipients of Reduced Intensity Conditioning Allo-HSCT with Acute Myeloid Leukemia in First Complete Remission: Integrating the Seattle Comorbidity Index (HCT-CI) and EBMT Scoring Systems*

Session Name: 721. Clinical Allogeneic Transplantation - Conditioning Regimens, Engraftment and Acute Transplant Toxicities: Toxicities

Session Date: Monday, December 10, 2012

Session Time: 4:30 PM - 6:00 PM

Presentation Time: 4:45 PM

Room: Georgia World Congress Center, C101

Presenter: Dr. J. Versluis.

4. Publication Number: 961

TITLE: *Equivalent Outcome Between Older Siblings and Unrelated Donors After Reduced Intensity Allogeneic Hematopoietic Stem Cell Transplantation for Patients Older Than 50 Years with Acute Myeloid Leukemia in First Complete Remission: A Report From the ALWP of EBMT*

Session Name: 731. Clinical Allogeneic and Autologous Transplantation - Results: Autologous or Allogeneic Transplantation

Session Date: Tuesday, December 11, 2012

Session Time: 7:30 AM - 9:00 AM

Presentation Time: 7:30 AM

Room: Georgia World Congress Center, B312-313a

Presenter: Dr. R. Peffault de Latour

ALWP MEETING AND SYMPOSIUM (Milan, Italy; November 9-10, 2012)

We take great pleasure in inviting you to attend the winter meeting of the ALWP followed by the fifth Symposium of the Acute Leukemia Working Party, organised by Dr F. Ciceri, and proudly hosted at the San Raffaele Scientific Institute in Milan, on November 9-10, 2012.

The first day of the meeting (November 9, 2012 – from 10.00 am to 5 pm) will be dedicated as usual to the ALWP studies and discussion of new proposals. The scientific symposium will take place on November 10, 2012 and will be dedicated this year to “Novel agents in stem cell transplantation”.

On behalf of the organising committee, we are looking forward to your active participation.

Organizing Secretariat:

Limes Srl – Fiorella Terrizzi
Via Melchiorre Gioia 171 – 20125 Milano
Tel.: +39/026697911 – Fax: +39/0267100597
segreteria@limesmed.com

**“Novel agents in stem cell transplantation”;
Milano, November 10, 2012**

Opening

10.00 – 10.15 Introduction; M Mohty, Paris

Session I – TK and Jak2 inhibitors prior and post transplant; Chairs: S. Giebel, J Esteve

10.15 – 10.45 Tyrosine Kinase Inhibitors; OG Ottmann, Frankfurt

10.45 – 11.15 Jak2 inhibitors; A Rambaldi, Bergamo

Session II – Conditioning; Chairs: NC Gorin, C Schmid

11.15 – 11.30 Clofarabine; M. Mohty, Paris

11.30 – 11.45 I.V. Busulfan; A Nagler, Tel Hashomer

11.45 – 12.00 Treosulfan; J Peccatori, Milano

12.00 - 12.15 Thiotepa ; F Aversa, Parma

12.30 – 13.30 Lunch

13.30 – 14.00 Lecture – How to design an Investigator-driven trials with new drugs in transplantation; G. Tognoni, Chieti

Session III – Post transplant immune modulation ; Chairs: M. Mohty, A. Nagler

14.00 – 14.15 Lenalidomide; P Corradini, Milano

14.15 – 14.30 Bortezomib; N Kroger, Hamburg

14.30 – 14.45 Bendamustine; L. Castagna, Milano

14.45 – 15.00 Azacytidine; C. Craddock, Birmingham

15.00 – 15.15 Rituximab; F Baron, Liege

15.15 – 15.30 FLT3 inhibitors; RF Schlenk, Ulm

15.30 – 16.00 Coffee break

Session IV – Cells are new drugs; Chairs: C. Bordignon, N. Kroger

16.00 – 16.15 Regulatory pathways in cell therapy; A. Aiuti, Milano


16.15 – 16.30 T cells engineering in transplantation; C Bonini, Milano

16.30 – 16.45 Invariant NKT cells; MT Rubio, Paris

16.45 – 17.00 Mesenchymal stem cells; F Locatelli, Roma

17.00 – 17.15 CIK cells; M Introna, Bergamo

17.15 Closing remarks; F Ciceri, S. Giebel, M. Mohty



Acute Leukemia Working Party
EBMT Paris Office
Hôpital Saint-Antoine
184, Rue du Faubourg Saint-Antoine
75571 Paris Cedex 12
France
Tel : +33.1.71.97.04.85
Fax : +33.1.71.97.04.88
E-mail: emmanuelle.polge@upmc.fr